Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive therapeutic target. The core splicing factor SF3B1 is hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Alors-Perez, Emilia, Blázquez-Encinas, Ricardo, Alcalá, Sonia, Viyuela-García, Cristina, Pedraza-Arevalo, Sergio, Herrero-Aguayo, Vicente, Jiménez-Vacas, Juan M., Mafficini, Andrea, Sánchez-Frías, Marina E., Cano, María T., Abollo-Jiménez, Fernando, Marín-Sanz, Juan A., Cabezas-Sainz, Pablo, Lawlor, Rita T., Luchini, Claudio, Sánchez, Laura, Sánchez-Hidalgo, Juan M., Ventura, Sebastián, Martin-Hijano, Laura, Gahete, Manuel D., Scarpa, Aldo, Arjona-Sánchez, Álvaro, Ibáñez-Costa, Alejandro, Sainz, Bruno, Luque, Raúl M., Castaño, Justo P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638119/
https://www.ncbi.nlm.nih.gov/pubmed/34857016
http://dx.doi.org/10.1186/s13046-021-02153-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638119/
https://www.ncbi.nlm.nih.gov/pubmed/34857016
http://dx.doi.org/10.1186/s13046-021-02153-9

Ejemplares similares